PAAT Act

This bill (HR 5467, the PAAT Act) requires Medicare Part D plans to cover specific drugs treating autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027. It directly affects Medicare beneficiaries with these conditions by mandating plan coverage for relevant medications. Key provisions include requiring plans to include all covered drugs for these conditions and prohibiting prior authorization for such drugs more than once per year, unless the drug is short-term, a controlled substance, or has a risk management strategy. The law aims to reduce coverage barriers for these treatments without altering drug approval or pricing.